Image description: T cell infected with HIV. Image Credit: National Institute of Allergy and Infectious Diseases (NIAID) In June of last year we wrote about how Dr. Scott Kitchen and his team at UCLA are engineering blood forming stem cells in order to fight HIV, a potentially deadly virus that attacks the immune system and … Continue reading CIRM funding helps improve immune cell therapy to combat HIV
Hitting our Goals: Let’s start at the beginning shall we
Way, way back in 2015 – seems like a lifetime ago doesn’t it – the team at CIRM sat down and planned out our Big 6 goals for the next five years. The end result was a Strategic Plan that was bold, ambitious and set us on course to do great things or kill ourselves … Continue reading Hitting our Goals: Let’s start at the beginning shall we
Meet xenobots 2.0 – the next generation of living robots
Xenobots scurry about and can work together in swarms. Source: Doug Blackiston Last year we wrote about how researchers at the University of Vermont and Tufts University were able to create what they call xenobots – the world’s first living, self healing robots created from frog stem cells. Now, the same team has created an … Continue reading Meet xenobots 2.0 – the next generation of living robots
Three UC’s Join Forces to Launch CRISPR Clinical Trial Targeting Sickle Cell Disease
Sickle shaped red blood cells The University of California, San Francisco (UCSF), in collaboration with UC Berkeley (UCB) and UC Los Angeles (UCLA), have been given permission by the US Food and Drug Administration (FDA) to launch a first-in-human clinical trial using CRISPR technology as a gene-editing technique to cure Sickle Cell Disease. This research … Continue reading Three UC’s Join Forces to Launch CRISPR Clinical Trial Targeting Sickle Cell Disease
Prime Time for Rocket
Rocket Pharmaceuticals, a company that specializes in developing genetic therapies for rare childhood disorders, just got a big boost from the European Medicines Agency (EMA). They were given a Priority Medicines (PRIME) designation for their therapy for Leukocyte Adhesion Deficiency-1 (LAD-1). CIRM is funding ($6.56 million) Rocket’s clinical trial for LAD-I, an immune disorder that … Continue reading Prime Time for Rocket
CIRM funding helps identify potential COVID-19 treatment
The steps of the virus growth cycle that can be targeted with therapies: The virus enters a host cell (1), the virus's genetic instructions are released, taking over cellular machinery (2), the virus is replicated within the cell (3) and copies of the virus exit the cell in search of new host cells to infect … Continue reading CIRM funding helps identify potential COVID-19 treatment
Hitting our Goals: Scoring a half century
Way, way back in 2015 – seems like a lifetime ago doesn’t it – the team at CIRM sat down and planned out our Big 6 goals for the next five years. The end result was a Strategic Plan that was bold, ambitious and set us on course to do great things or kill ourselves … Continue reading Hitting our Goals: Scoring a half century
Newly designed “bioink” get us one step closer to 3D printed organs
3D bioprinted small airways made out of two cell types (blue and yellow) remain open over time. 3D printing technology has revolutionized the way we think about creating things with complex designs with the simple click of a button. The ability to be able to give a computer a specific set of instructions and hit … Continue reading Newly designed “bioink” get us one step closer to 3D printed organs
Going the extra mile to save a patient’s life
You can tell an awful lot about a company by the people it hires and the ability it gives them to do their job in an ethical, principled way. By that measure Rocket Pharma is a pretty darn cool company. Rocket Pharma is running a CIRM-funded clinical trial for Leukocyte Adhesion Deficiency-I (LAD-I), a rare … Continue reading Going the extra mile to save a patient’s life
Hitting our goals: regulatory reform
Way, way back in 2015 – seems like a lifetime ago doesn’t it – the team at CIRM sat down and planned out our Big 6 goals for the next five years. The end result was a Strategic Plan that was bold, ambitious and set us on course to do great things or kill ourselves … Continue reading Hitting our goals: regulatory reform
The Stem Cellar 